在HFrEF中进行重塑的ARNI对比Perindopril. 一个队列研究研究
Noor Muhammad Azlan Shah Bin Atan1, Mohd Firdaus Bin Hadi1, Victoria Wen Yeng Teoh1
1Department of Medicine, University Malaya Medical Centre, Kuala Lumpur, Malaysia.
Journal of cardiovascular pharmacology and therapeutics
|August 28, 2023
概括
ангиотензин受体-neprilysin 抑制剂 (ARNI) 和大兴都改善了心力衰竭患者的射出分数. ARNI显示出更强的重塑效应,显著减少左心室末缩体积.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医学研究 医学研究
背景情况:
- 心室重塑是心力衰竭中具有减少喷射率 (HFrEF) 的有害过程.
- ангиотензин转化酶抑制剂和萨库比特里尔/瓦尔沙坦在观察性研究中已经证明了重塑逆转.
- 这些治疗方法的对比比较是有限的.
研究的目的:
- 在HFrEF患者中,比较血管新生素受体-neprilysin抑制剂 (ARNI) 与大肠的心室重塑效应.
- 为了评估左心室喷射分数 (LVEF),终端透缩体积 (LVEDV) 和终端抽缩体积 (LVESV) 的变化.
主要方法:
- 在2017-2020年期间接受治疗的HFrEF患者 (EF<40%) 的队列研究.
- 在ARNI组中,患者接受了ARNI或大兴,在ARNI组中没有先前使用氨酸-血管新生素-阿尔多斯特系统抑制剂.
- 心声学在基线和治疗后6-18个月评估了LVEF,LVEDV和LVESV.
主要成果:
- 在9个月后,ARNI和百度普利都显著改善了LVEF (分别增加11.5%和11.8%).
- ARNI导致LVEDV (8.4毫升与3.2毫升相比) 和LVESV (17.9毫升与10.8毫升相比) 的减少更大.
- 随着ARNI的使用,LVESV的减少在统计学上显著 (P = .007).
结论:
- 在9个月内,ARNI和二都有效地改善了HFrEF患者的LVEF.
- ARNI显示出潜在的更强的心室重塑效应,特别是在减少左心室体积方面.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:25Aortic Regurgitation III: Medical Management
25
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
25
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
689
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
689
01:29Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
778
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
778